Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-DFO-YS5 PET Imaging in Prostate Cancer
NCT05245006Phase 1Active, not recruiting
- Start
- Mar 2022
- Primary completion
- Jul 2027
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of FG-3180 in metastatic castration-resistant prostate cancer (mCRPC) (3 cohorts). Primary endpoints: Optimal time point for imaging using 89Zr-DFO-YS5 PET post-injection at 7 days, Optimal antibody dose for imaging using 89Zr-DFO-YS5 PET at 7 days and 3 more. Started Mar 2022; status: active, not recruiting.
02
Drugs
FG-3180
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05245006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05245006.